| SEC Form 4 |   |
|------------|---|
| FORM       | 4 |

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| Check this box if no longer subject to<br>Section 16. Form 4 or Form 5<br>obligations may continue. See<br>Instruction 1(b) |
|---|
| Instruction 1(b).   |

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| OMB APPF                 | Roval |  |  |  |  |  |  |  |
|--------------------------|-------|--|--|--|--|--|--|--|
|                          |       |  |  |  |  |  |  |  |
| OMB Number: 3235-0287    |       |  |  |  |  |  |  |  |
| Estimated average burden |       |  |  |  |  |  |  |  |
| hours per response:      | 0.5   |  |  |  |  |  |  |  |

| 1. Name and Address of Reporting Person* |               | Person <sup>*</sup> | 2. Issuer Name and Ticker or Trading Symbol<br><u>Roivant Sciences Ltd.</u> [ ROIV ] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) |                               |                       |  |  |  |
|--|---------------|---------------------|--|---|-------------------------------|-----------------------|--|--|--|
| Gline Matthew                            |               |                     |  | 1   | Director                      | 10% Owner             |  |  |  |
|  |               |                     | -  | 1   | Officer (give title           | Other (specify        |  |  |  |
| (Last) (First) (Middle)                  |               | (Middle)            | 3. Date of Earliest Transaction (Month/Day/Year)                                     |   | below)                        | below)                |  |  |  |
| C/O ROIVA                                | NT SCIENCES I | LTD.                | 10/20/2024   | 1   | CEO                           |                       |  |  |  |
| 7TH FLOOP                                | R, 50 BROADWA | AY                  |  |   |                               |                       |  |  |  |
|  |               |                     | 4. If Amendment, Date of Original Filed (Month/Day/Year)                             |   | vidual or Joint/Group Fil     | ing (Check Applicable |  |  |  |
| (Street)                                 |               |                     |  | Line)   |                               |                       |  |  |  |
| LONDON                                   | X0            | SW1H 0DB            |  | 1   | Form filed by One Re          | eporting Person       |  |  |  |
|  |               |                     | -  |   | Form filed by More the Person | nan One Reporting     |  |  |  |
| (City)                                   | (State)       | (Zip)               |  |   |                               |                       |  |  |  |

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction<br>Date<br>(Month/Day/Year) | 2A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | Code | Transaction Disposed Of (D) (Instr. 3, 4 a<br>Code (Instr. 5) |           |               | Securities<br>Beneficially |                                    | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |            |
|---------------------------------|--|---|------|---|-----------|---------------|----------------------------|------------------------------------|---|------------|
|                                 |  |   | Code | v   | Amount    | (A) or<br>(D) | Price                      | Transaction(s)<br>(Instr. 3 and 4) |   | (11150. 4) |
| Common Shares                   | 10/20/2024                                 |   | F    |   | 10,945(1) | D             | \$11.92                    | 17,361,059                         | D   |            |

#### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

|   | (e.g., puis, cais, warrants, options, convertible securities)         |  |   |                              |   |                 |     |  |                    |           |  |  |  |  |  |
|---|---|--|---|------------------------------|---|-----------------|-----|--|--------------------|-----------|--|--|--|--|--|
| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction<br>Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 4.<br>Transa<br>Code (<br>8) |   | 5. Number<br>of |     | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) |                    | Amount of |  | Amount of Derivative<br>Securities Security<br>Inderlying (Instr. 5)<br>Derivative<br>Security (Instr. |  | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|   |   |  |   | Code                         | v | (A)             | (D) | Date<br>Exercisable  | Expiration<br>Date | Title     | Amount<br>or<br>Number<br>of<br>Shares |  |  |  |  |

### Explanation of Responses:

1. Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.

By: /s/ Jo Chen, as Attorney-10/22/2024

in-Fact for Matthew Gline

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.